Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9103204 | 1.00 | CHRM2 (0.39) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL9102709 | 0.98 | CHRM2 (0.41) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL9102725 | 0.98 | CHRM2 (0.41) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL9288110 | 0.90 | MAOA (0.36) | MAOAMAOB | |
| SCHEMBL9288106 | 0.90 | MAOA (0.36) | MAOAMAOB | |
| SCHEMBL9100703 | 0.89 | HRH3 (0.39) | HRH3 | |
| SCHEMBL9100697 | 0.89 | HRH3 (0.39) | HRH3 | |
| SCHEMBL9103026 | 0.89 | HRH3 (0.39) | HRH3 | |
| SCHEMBL9102281 | 0.89 | CHRM2 (0.40) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL9886367 | 0.88 | DRD4 (0.37) | SIGMAR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082731-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-24 | — | — | WO | disclosed |
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | CHRM2 55/4885ADRA2B 165/4885DRD3 1463/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | CHRM2 55/4885ADRA2B 165/4885DRD3 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.